AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus Launches Worldwide Academic Access Program for its Flagship Ontosight.ai
Frankfurt, Germany, May 21, 2019 — Innoplexus announced today the launch of Ontosight Academic, a platform that provides academic researchers free access to a vast volume of life sciences data made searchable using machine learning algorithms and other artificial intelligence technologies. Today, academic researchers in life sciences are swamped with millions of publications and theses that they use to validate a hypothesis or to find a relevant connection. This research is important because it has the potential to improve quality of life for everyone. For this reason, Innoplexus aims to remove certain limitations to academic research by democratizing data and supporting research conducted by life science academics, thereby facilitating progress in this area. After collaboration with selected universities in the United States since last year, Innoplexus is now launching the academic access program worldwide. The platform is available to academic life sciences researchers at ontosight.ai/academic.
Innoplexus’s Ontosight Academic platform leverages its life science data ocean with a self-learning life sciences-specific ontology along with natural language processing to provide search results that are more industry specific and relevant to the search query. The life sciences ontology developed by Innoplexus enables concept-based contextual and accurate results generated from over 95% of publicly available life sciences data. “Knowledge is growing faster than our ability to effectively absorb and apply it in research. It is estimated that by 2020 the amount of medical knowledge will double every 73 days. What medical students who will graduate that year learned during the first 3 years of their studies will represent only 6% of the knowledge accumulated by the medical world in the decade that ends in 2020,” says Dr. Gunjan Bhardwaj, CEO and founder of Innoplexus. “Therefore, we support researchers to further scientific development by giving them faster and better access to all the data. We are driven by our determination to help science win.”
Innoplexus leverages machine learning algorithms to make this data structured and available for generating useful, real-time insights by academic researchers. With its proprietary technology, which crawls, aggregates, analyzes, and visualizes data from various scientific resources such as publications, clinical trial repositories, drug profiles, gene profiles, theses, dissertations, grants, and patents, Innoplexus ensures access to even the most nascent research being done in their field.
Featured News
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trials BOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…
Innoplexus signs MoU to provide academic license for its iPlexus
Innoplexus is proud to announce our collaboration with the Regional Cancer Centre, Gwalior. Innoplexus has executed an MoU to provide…
